article thumbnail

Vertex signs licence deal with CRISPR Therapeutics for diabetes therapies

Pharmaceutical Technology

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). A Phase I/II study of VCTX211 has been commenced and is currently ongoing. It originated under the partnership of CRISPR Therapeutics and ViaCyte.

article thumbnail

Lilly and ProQR to expand genetic medicine development agreement

Pharmaceutical Technology

The latest development comes after Lilly and Sosei Heptares signed a partnership for developing small molecules that modulate new G protein-coupled receptor targets linked to diabetes and metabolic diseases. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SEO Campaigns for Pharma Marketing: Strategies to Boost Visibility and Engagement

Pharma Marketing Network

Educational Content for Patients and Providers: Publish blog posts, white papers, and infographics that address common questions and concerns. Understanding Diabetes Management) with trending topics (e.g., For instance, articles like How Stelara Works for Crohns Disease can establish authority and provide value.

article thumbnail

Mastering Pharmaceutical Marketing: Strategies to Drive Success in the Pharma Industry

Pharma Marketing Network

For instance, Ozempic campaigns have succeeded by showcasing its dual benefits for managing diabetes and weight loss. Develop blogs, white papers, and videos that educate and engage. Highlighting Innovation Patients and HCPs alike value innovation. If your drug has a unique mechanism of action, emphasize it.

article thumbnail

Pharma must adapt to embrace the opportunities of a new-look NHS

pharmaphorum

A new focus on “place” and the introduction of medicines registers are among the proposals in a new government white paper on the future of NHS England. Said Thorne: “Of course Liverpool should have a different diabetes strategy to rural East Anglia. Despite this, he said, very few pharma companies were mapping out the “places”.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.

article thumbnail

The “Medical Bypass”: new drugs to strike obesity

Pharmaceutical Technology

The drug was approved to treat type 2 diabetes mellitus in May. High rates of obesity place a major burden on healthcare systems as the condition is associated with many major health complications like type 2 diabetes, hypertension, non-alcoholic fatty liver disease, and other bodily dysfunctions. Anti-obesity therapeutic landscape.